CGBio is launching Novomax Fusion, a ceramic-based cervical fusion cage, to the Japanese spinal implant market. It is the first CGBio spinal implant product to be introduced to the region.
Novomax Fusion is a third-generation cervical spine cage that utilizes BGS-7 (calcium-silica-phosphorus-boron composition), a new bioactive glass-ceramic material developed by CGBio. The product is more biocompatible than existing titanium or PEEK cages, and it and excellent osteoconductivity, creating an environment that facilitates bone growth.
When inserted into the body, fusion is achieved by directly attaching the bone to the surface of the cage, and stable bone fusion can be induced without the need for a separate bone graft material.
Novomax Fusion will be supplied to the Japanese market through the distributor ZSpine. This agreement marks CGBio’s first entry into the Japanese market with an official distribution partner.
“By the entry of Novomax Fusion, we have once again demonstrated the superiority and clinical potential of our new BGS-7 material in Japan, which is recognized as a technology leader,” CGBio CEO Yu Hyun-seung said. “We plan to enter the global market for our next-generation spinal implant family, including the expandable cage Excender.”
CGBio is launching Novomax Fusion, a ceramic-based cervical fusion cage, to the Japanese spinal implant market. It is the first CGBio spinal implant product to be introduced to the region.
Novomax Fusion is a third-generation cervical spine cage that utilizes BGS-7 (calcium-silica-phosphorus-boron composition), a new bioactive glass-ceramic...
CGBio is launching Novomax Fusion, a ceramic-based cervical fusion cage, to the Japanese spinal implant market. It is the first CGBio spinal implant product to be introduced to the region.
Novomax Fusion is a third-generation cervical spine cage that utilizes BGS-7 (calcium-silica-phosphorus-boron composition), a new bioactive glass-ceramic material developed by CGBio. The product is more biocompatible than existing titanium or PEEK cages, and it and excellent osteoconductivity, creating an environment that facilitates bone growth.
When inserted into the body, fusion is achieved by directly attaching the bone to the surface of the cage, and stable bone fusion can be induced without the need for a separate bone graft material.
Novomax Fusion will be supplied to the Japanese market through the distributor ZSpine. This agreement marks CGBio’s first entry into the Japanese market with an official distribution partner.
“By the entry of Novomax Fusion, we have once again demonstrated the superiority and clinical potential of our new BGS-7 material in Japan, which is recognized as a technology leader,” CGBio CEO Yu Hyun-seung said. “We plan to enter the global market for our next-generation spinal implant family, including the expandable cage Excender.”
Copy to clipboard 
